Background: Studies indicate that in most patients with chronic hepatitis C, viral RNA is present not only in plasma but also in Peripheral Blood Mononuclear Cells (PBMC). Furthermore, the PBMC compartment may be a preferred site for HCV, which is able to reinitiate viral replication after HCV treatment, even if clearance occurred. The aim of this study was to detect the persistence of hepatitis C viral RNA in both serum and PBMCs at 12 and 24 weeks of treatment in chronic hepatitis C virus (CHC) patients with sofosbuvir based therapy. Methods: 75 CHC patients were tested for HCV-RNA in serum at 0, 12 & 24 weeks of treatment, and for HCV-RNA in PBMCs on the 12 & 24 weeks. Results: At week 12 of treatment all patients had no HCVRNA in their serum; however, 8 cases were positive for HCV RNA in their PBMC. After 24 weeks of treatment, HCV RNA was re-examined in both serum and PBMCs for all patients. Six out of the eight cases that were found having positive
HCV RNA in their PBMCs turned positive HCV RNA in the serum. While the other two cases still negative for HCV RNA in the serum. Interestingly, another two cases out of the sixty-seven cases that were found having negative HCV RNA in their PBMC turned positive HCV RNA in the serum. Conclusions: Absence of HCV RNA in PBMC is a better predictor of good response after treatment of CHC patients with DAAs, than its absence in the serum.
Background
Hepatitis C virus (HCV) is infects over 170 million people world-wide. It causes chronic hepatitis in up to 85% of those infected. In a significant number of patients, chronic hepatitis C (CHC) eventually progresses to fibrosis and cirrhosis in 35% of patients, 3% of whom would develop hepatocellular carcinoma (HCC) [1, 2] .
The highest prevalence of hepatitis C in the world was found in Egypt. Overall, estimates of the HCV rate in the general population range between 10 and 20%. In 2015, the prevalence of HCV in Egypt was found to be 10.0% in the 15-59 year age groups [3, 4] . Acute HCV infection is often asymptomatic and the great majority of patients develop chronic hepatitis [5] .
HCV screening depends on serological detection of anti HCV antibodies by Enzymelinked immunosorbent assay (ELISA) that has to be confirmed by detection of HCV-RNA in the serum by reverse transcription polymerase chain reaction (RT-PCR) [6] but both tests do not allow for cell specific localization of HCV. Furthermore, repeatedly negative RT-PCR for HCV-RNA in serum does not conclude the absence of HCV in the liver [7] .
HCV is mainly a hepatotropic virus with minor extrahepatic compartments replication accounting for about 3.1% of the virus in circulation [8, 9] . Hellings et al first described HCV infection of lymphoid cells in 1985 [10] . The minus strand HCV RNA and the replicative intermediate form of HCV were detected in the peripheral blood mononuclear cells (PBMCs) indicating HCV replication inside [11, 12] Direct acting antiviral drugs (DAAs) are new drugs that have shown superior efficacy in achieving a sustained virologic response (SVR), the ultimate HCV treatment. They target specific non-structural proteins of the virus and results in disruption of viral replication and infection. There are four classes of DAAs, non-structural proteins NS3/4A protease inhibitors (Simiprevir, paritaprevir), NS5B nucleoside polymerase inhibitors (Sofosbuvir), NS5B non-nucleoside polymerase inhibitors (Dasabuvir), and NS5A inhibitors (Daclatasvir) according to their mechanism of action and therapeutic target [13] .
National protocol of HCV treatment used in Egyptian Patients infected with HCV (genotype 4) is a combination of daily sofosbuvir and any other direct acting antiviral drugs for 12 weeks. Compared to previously used treatments, sofosbuvirbased regimens provide a higher cure rate, fewer side effects, and a two-to fourfold reduction in duration of therapy. It allows most people to be treated successfully without the use of peg interferon. [14] .
The importance of checking for the presence of HCV RNA in PBMC lies in its implication as HCV reservoir. It has been demonstrated that low-level intrahepatic viral load despite negative serum HCV RNA has been associated with viral relapse, particularly in the setting of immune suppression. Moreover, the detection of HCV RNA in PBMC might have important implications for effective therapy and the plane of treatment. [15] .
Methods
The aim of the present study was to investigate the persistence of HCV RNA in both serum and peripheral blood mononuclear cells at 12 and 24 weeks of treatment of Egyptian CHC patients with DAAs.
Study design: observational prospective study
This study was carried out after the approval of the Ethical Committee of Medical Research Institute. A signed informed consent was obtained from all patients enrolled in the study. This study included seventy-five CHC patients selected from the outpatient clinic of the Medical Research Institute, Alexandria University.
Criteria of patients' selection:
According to the national protocol of treatment of CHC in Egypt, they were positive for HCV antibody and HCV RNA before treatment. Blood was collected from the patients after overnight fasting in a 10 mL tube. 5 ml were used for serum serum separation and aliquoted to be stored at -20°C. the other 5 mls were used for the separation of PBMC and collected into heparin containing tubes. Immediately after collection, the cells were separated from whole blood by centrifugation on a Ficoll-Hypaque density gradient. Aliquots of 10 6 PBMC was pellet and stored at -80 o C. [16] A) Quantitative detection of HCV RNA by reverse transcriptase PCR (RT-PCR) from serum (At 0, 12, 24 weeks of treatment). [17] HCV specific RNA was extracted from serum samples (140 μL) using QIAamp viral RNA Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Tenml of extracted HCV-RNA was amplified using HCV Qiagen kit (Artus, QS-RGQ (72) ref.
4518366 HCV PCR kit). Real time PCR was performed with the Mx3000P TM (Stratagene) real time PCR system. The procedure included; first, incubation at 50°C for 30 min to transcribe viral RNA to cDNA by RT , AmpliTaq gold activation for 95° C for 10 min, then 40 cycles of two PCR-step amplification, denaturation for 95°C for 15 sec, Lastly, annealion and extension at 50° C for 1 min and 72 ° C for 30 min respectively. The fluorescence detection was then performed. [18, 19] HCV RNA extraction was performed from10 6 Amplified Samples were then analyzed using 2% agarose gel electrophoresis.
B) Qualitative detection of HCV RNA from PBMC

Results
Age and sex distribution: Among the 75 cases included in this study 51(68%) were females and 24 (32%) were males. Out of the 75 cases included in this study; 9(12%) were between 25 to 35 years, 45(60%) were between 36 and 45 and 21(28%) were between 46 and 60 years old. (Table 1) Laboratory investigation results: (Table I) Liver function tests: 48 cases (64%) had elevated liver enzymes and 27 cases (36%) had normal liver enzymes before the start of the treatment.
All patients had serum albumin > 3.5g, serum bilirubin <1.2mg, platelet count > 150,000/mm 3 and INR <1.2 before the start of the treatment HCV -RNA Viral load before treatment: 6 cases (8%) had viral load less than 10 4 , 39 cases (52%) had viral load ranging from 10 4 to less than 10 6 and 30 cases (40%) had viral load more than 10 6 before the start of the treatment. In the present study, no correlation was found between either age with cirrhosis or viral load. Also, no correlation was found either between viral load and cirrhosis or liver enzymes.
HCV RNA distribution in both serum and PBMCs at both weeks (12 and 24)
of treatment: At the beginning of the treatment, the 75 patients had viral loads ranging from 10 3 to 10 7 IU/ml. All patients enrolled in this study showed end of treatment response to therapy at week 12 (100%). However, after 12 weeks of treatment, only 8 cases (10.7%) out of 75 chronic HCV included in this study were HCV RNA positive in their PBMC. After 24 weeks of treatment, HCV RNA was re-examined in both serum and PBMC for all patients. Six out of the eight cases that were found having positive HCV RNA in their PBMCs turned positive HCV RNA in the serum. While the other two cases became negative for HCV RNA in both serum and PBMC. Interestingly, another two new cases out of the sixty-seven cases that were found having negative HCV RNA in their PBMC turned positive HCV RNA in the serum. SVR at week 24 was achieved in sixty-seven cases out of the seventy-five cases included in the study (89.3%). Table II, Figure (1&2) .
Comparison between SVR rate in patients positive and negative for HCV
RNA in PBMC at the end of treatment: SVR rate is significantly higher in Patients negative for HCV RNA at both serum and PBMCs (97%) than those who were negative for HCV RNA at the serum but positive in PBMCs at the end of treatment (25%). (x 2 =38.896) (P < 0.001). (Table III) 
Discussion
Our study demonstrates no correlation between the HCV viral load and the age of the patients, which was also supported by previous studies [20, 21] . Both a direct viral effect and an immune-mediated response may play a role in the pathogenesis of liver injury by HCV [22] . However, no such correlation between viral load and degree of liver injury was found in the present study.
Studies evaluating the relationship between serum viral load and the severity of abnormalities in liver reported conflicting results; as some studies correlated high level viremia with advanced stage liver disease [23] while others found no correlation with either cytology or aminotransferase activities [24] [25] [26] .
No correlation was found between liver enzymes and viral load in the current study.
Similar results were demonstrated by other investigators [27] [28] [29] [30] .
Direct acting antiviral drugs (DAAs) are new drugs that have shown >90% efficacy in achieving the goal of treatment of chronic HCV infection which is a sustained virologic response (SVR). [13] . All CHC patients included in this study were treated with DAAs and showed a higher SVR rate to therapy (89.3%) defined as the complete absence of detectable serum HCV RNA at week 24 of therapy. This high SVR rate was due to a good selection of the cases as all cases were child (A).
Lymphoid cells may offer favorable reservoirs leading to HCV persistence and chronicity. The latency of HCV virus is still poorly understood [31] Some studies stated that in most patients with chronic hepatitis C showed simultaneous coexistence of viral RNA in plasma and in PBMC. The persistence of HCV RNA in extrahepatic reservoirs could markedly affect disease management. So, despite clearance of HCV from hepatocytes is achieved by treatment, re-infection from extra-hepatic sites, such as the PBMC may occur [32, 33] All patients included in this study showed viral response to therapy at week 12, however, at the same time, HCV RNA was still detected in freshly isolated peripheral blood mononuclear cells of (10.7%) of them. After 24weeks of initiating treatment, these patients were retested for the presence of HCV RNA in both serum and PMNCs.
Six out of the eight cases that were found having positive HCV RNA in their PBMCs turned positive HCV RNA in the serum. While the other two cases still negative for HCV RNA in the serum. And interestingly another two new cases out of the sixtyseven cases that were found to have negative HCV RNA in their PBMCs turned positive HCV RNA in the serum. This denotes that although patients showed complete response at 12 weeks, it did not signify that the patients would acquire sustained viral response.
In addition to the detection of positive-stranded HCV RNA in PBMC, the presence of negative-stranded HCV RNA in PBMC implies viral replication as well as argues against serum viral particles passively adhering to the cells. [34, 35] Moreover, cytoplasmic staining of the monocyte fraction of PBMC for HCV core antigen proves the hypothesis that PBMC contain virus [36] . Also, in chronic HCV patients, HCV genome was detected in PBMC by in situ hybridization. Lastly, HCV-RNA sequences were found in the PBMC, but negative in serum containing the cell preparation of some patients [37] . Similar results were reported by Philippe, who found that 77% of chronic HCV patients were HCV RNA positive in PBMCs [38] In addition, it was found that the positivity of HCV RNA in PBMC could occur concomitantly with negative HCV RNA in serum. Similarly, Ping et al [39] showed that the positive rate of HCV RNA in PBMC of patients with chronic hepatitis C was much higher than that of patients with acute hepatitis C.
Abdelfattah et al [40] reported the presence of detectable HCV RNA in the PBMCs of 12% of patients at week 12 of treatment, and all patients were negative for HCV RNA in their sera at the end of the course of interferon based treatment and at the same time, HCV RNA was still detected in freshly isolated peripheral blood mononuclear cells of approximately 32% of these patients.
Abdelfattah et al [40] observed that patients who tested positively for HCV RNA in PBMCs at the end of treatment had a higher relapse rate (50%) when compared with patients who tested negatively for HCV RNA in both serum and PBMCs at the end of treatment (6%). These results were in accordance with our findings, as we found a significant higher relapse rate in patients who tested positively for HCV RNA in PBMC at the end of treatment (75%) when compared with patients who tested negatively for HCV RNA in both serum and PBMCs at the end of treatment (3%) .
This may give a clue to the role played by the persistence of HCV RNA in PBMC on the outcome of the treatment.
Similar results were reported by Zayed et al. [41] and Gong et al. [42] , they suggested that one of the factors influencing response to HCV therapy would be the replicative minus-strand HCV RNA in PBMCs.
On the other hand, Bernardin et al. [43] could not find any detectable HCV RNA in PBMC of 69 non-viremic donors. He implied that PBMCs are unlikely to serve as a long-lived reservoir of HCV in non-viremic subjects. But this cannot role out effective replication of HCV in the PBMCs in those exposed to HCV infection.
Conclusions
Absence of HCV RNA in PBMCs is a better predictor of good response after treatment of CHC patients with DAAs, than its absence in the serum. 
